Spiracur

About Spiracur

Spiracur, Inc. operated as a medical device company with a specific focus on developing advanced wound healing technologies. The company emerged from the Stanford Biodesign Innovation Program in 2007, founded by Moshe Pinto, Kenton Fong, and Dean Hu. The founders' goal was to address the treatment of chronic ulcers at an earlier, less severe stage to prevent more serious complications.

The company's core product was the SNaP® (Smart Negative Pressure) Wound Care System, a novel approach to Negative Pressure Wound Therapy (NPWT). Traditional NPWT systems relied on bulky, electrically powered pumps, which limited patient mobility and presented logistical challenges for clinicians. Spiracur's key differentiator was that its SNaP system was mechanically powered, using specialized tension springs to generate continuous, controlled negative pressure to a wound bed. This design made the device lightweight, portable, disposable, and operable without electricity or batteries. The system was intended for ambulatory patients being treated at home and was available off-the-shelf, contrasting with the rental-based model of its electronic counterparts. It served patients with a variety of wounds, including chronic, acute, traumatic, subacute, and dehisced wounds, as well as ulcers and partial-thickness burns.

Spiracur's business model involved the sale of these single-use, disposable devices to healthcare providers. The company achieved significant milestones, including FDA clearance for the SNaP System in August 2009 under a new "non-powered" NPWT device category and obtaining the CE Mark for European distribution in December 2010. Over its lifetime, Spiracur raised approximately $55.3 million in funding from investors such as Kleiner Perkins, De Novo Ventures, and Maverick Ventures. Despite its product's advantages, the company faced significant hurdles with reimbursement, which hampered growth. In December 2015, Acelity (the parent company of KCI) acquired Spiracur's SNaP business, integrating the technology into its extensive wound care portfolio. Subsequently, 3M acquired Acelity and its subsidiaries in 2019, which included the patents originating from Spiracur.